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Summary
Objective: We aimed to document current practice in the medical management of paediatric hyperthyroidism in the 
UK and compare to international recommendations. 
Design: A 27 question online survey was distributed via an electronic newsletter in August 2018.
Participants: Members of the British Society for Paediatric Endocrinology and Diabetes. 
Measurements: We collected information about anti-thyroid drug (ATD) preference, treatment duration, criteria used 
to monitor full blood count (FBC), management of neutropaenia, agranulocytosis screening and patient education. 
Results: Carbimazole is favoured by 98% of respondents and a ‘dose titration’ regimen preferred over ‘block and 
replace’ (65% versus 29%). TRAbs (Thyroid Receptor Antibodies) are used for diagnostic purposes by 85% and by 33% 
to look for evidence of disease remission. The majority (81%) treat for a minimum of 2 years before considering a trial 
off ATD. All respondents reported that they ‘always/usually’ warn their patients about the risk of agranulocytosis 
before starting ATD, but written information is ‘rarely/never’ provided by 63%. Sore throat (98%) and fever (92%) are 
the most commonly cited symptoms used to alert a patient to possible agranulocytosis. FBC is measured prior to 
treatment by 65% and measured periodically during treatment by 70%. 
Conclusions: The management of paediatric hyperthyroidism with ATDs in the UK is not consistent with all 
international recommendations because a block and replace ATD regimen remains widely used. TRAbs are utilised at 
presentation, but under-used for detecting disease remission. National consensus guidelines and written patient 
information may refine the management of paediatric patients on ATDs.
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1 Introduction
The incidence of hyperthyroidism in children in the UK and Ireland is 0.9 per 100,000 and is due to underlying Graves’ 
disease in 96% of cases.1 Medical treatment consists of thionamide anti-thyroid drug (ATD) using Carbimazole (CBZ), 
its active metabolite Methimazole, or Propylthiouracil (PTU). Only CBZ and PTU are available in the UK. The United 
States Food and Drug Administration released a warning in 2010 regarding the increased risk of hepatotoxicity 
associated with PTU in children and, as a result, CBZ is recommended as first-line treatment, with the exception of the 
first trimester of pregnancy.2-6 ETA (European Thyroid Association) and ATA (American Thyroid Association) guidelines 
advise on treatment for adults and children. Both advocate the use of CBZ over PTU in children. The ATA recommend 
a treatment duration of 12-24 months, and the ETA a treatment duration of 36 months prior to stopping ATD therapy 
in children to check for remission.2,3 JTA (Japanese Thyroid Association) guidelines are paediatric specific and 
recommend treatment with Methimazole for a duration of 18-24 months.4
ATD therapy typically involves either titrating the dose of ATD until the patient becomes euthyroid (dose titration, DT) 
or maintaining a high dose of ATD to suppress endogenous thyroid production and then replacing thyroid hormone 
with Levothyroxine (block and replace, BR). BR may require fewer hospital visits and blood tests whilst DT is associated 
with fewer ATD side-effects because of the lower ATD dose.1,3,7 ETA guidelines do not advocate one treatment regimen 
over the other but the ATA recommend DT. JTA guidelines recommend avoiding BR, citing the 2010 Cochrane 
Collaboration review that identified an increased risk of adverse reactions with this treatment strategy when 
compared to  DT.4,7 However it has been highlighted that some of the studies included in the Cochrane review, and in 
the BR section of the analyses, used an ATD dose that was much higher than routinely used in clinical practice.8  The 
Cochrane review also focused on the use of ATD in the context of adults and not the management of children and 
adolescents.
A rare but potentially fatal side effect of ATD therapy is agranulocytosis, defined as an absolute neutrophil count (ANC) 
of < 0.5 x109/L.9 It is important that patients are aware of the need to have their full blood count (FBC) checked when 
they experience symptoms suggestive of agranulocytosis. Symptoms are non-specific, most commonly fever and sore 
throat in adults presenting with agranulocytosis secondary to ATDs.10 Although it is recommended that patients are 
provided with written information about the risk of agranulocytosis, international guidelines do not specify symptoms 
which should trigger consideration of agranulocytosis or measurement of an FBC.2,3 Recommendations in the UK 
suggest that three measures should be taken to manage the risk of  agranulocytosis: Patients should be asked to report 
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symptoms of infection; a white blood cell count should be performed when there is clinical evidence of infection; and 
CBZ should be stopped promptly if there is clinical or laboratory evidence of neutropaenia.11 
We set out to establish the current approach to ATD use in children in the UK. We also sought to understand how the 
risk of agranulocytosis is managed, exploring how clinicians might respond to blood tests demonstrating a low white 
cell count. We also explored clinician’s use of TRAb (Thyroid Receptor Antibody) measurement and the typical duration 
of ATD treatment in children with hyperthyroidism. 
2 Materials and Methods
We developed and then advertised a 27-question online survey in the BSPED (British Society for Paediatric 
Endocrinology and Diabetes) newsletter e-mailed to all members in July and August of 2018, with a subsequent follow 
up email designed to boost the response rate. Respondents could choose to remain anonymous if preferred. The 
questions were multiple choice but 13 of the qu stions also included an option for free text. The full list of questions 
in the survey can be found at goo.gl/forms/7gbi8MnV6uZ7Umyg2. 
The first seven questions sought demographic data about the respondent, the service that they work in as well as 
establishing whether a hyperthyroidism guideline was in use. Three questions elicited their ATD of choice, whether 
they had a preference for DT or BR and whether they perform an FBC prior to ATD initiation. Respondents were then 
posed six questions exploring whether patients are warned about agranulocytosis, whether this includes written 
patient information, whether the warnings are repeated at follow up and whether there is a systemic warning system 
in place to remind clinicians to discuss the risk of agranulocytosis. We further explored the management of 
agranulocytosis with two questions pertaining to how patients are taught to recognise and react to agranulocytosis, 
and a question regarding the clinicians’ actions should they be confronted with a range of low neutrophil counts. The 
following three questions explored the use of TRAbs and other factors that might influence the length of ATD 
treatment, with four further questions about the experience of the respondent within paediatric endocrinology and 
how many cases of agranulocytosis or hepatic impairment they had encountered secondary to ATD use. We used 
conditional branching within the survey to divert respondents away from questions that were not relevant to them. 
The survey remained open to responses for 6 weeks. 
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We used descriptive statistics to quantify responses to each question, calculating the percentage of responses to each 
question using the number of respondents to that question as the denominator. We collated and analysed data within 
Microsoft Excel (MSO 16, Microsoft Corporation, Redmond, WA, USA). 
As the study was a survey on healthcare provision and did not collect individual patient information, research ethics 
approval was not required.
3 Results
3.1 Demographics
The BSPED committee sent the newsletter to 437 members, of whom 266 are medical consultants. We received a total 
of 48 responses (11%), of which 32 were from clinicians in a tertiary centre and 16 from a secondary centre. 
Respondents comprised 30 consultant paediatric endocrinologists, 16 consultant paediatricians with a special interest 
in endocrinology, and two paediatric doctors in training. Respondents collectively reported 519 years of experience in 
paediatric endocrinology, with 63% (30/48) of respondents having over 10 years of experience in the field and only 
three respondents reporting less than two years of experience in the field. The majority (54%, 26/48) of respondents 
had never encountered a patient with agranulocytosis secondary to ATD use, whilst 44% (21/48) had seen one or two 
cases, and one individual three or four cases. 
3.2 Management of Hyperthyroidism
Guidelines for the treatment of hyperthyroidism are used by 21% (10/48) of respondents. Five use a local trust 
guideline, one a local network guideline, and four a national or international guideline. CBZ is the first line ATD used 
by 98% (47/48) of respondents, with 65% (31/48) reporting a preference for DT, 29% (14/48) for BR and 6% (3/48) 
reporting no preference (Figure 1).
TRAb’s are used to assist diagnosis by 85% (41/48) of respondents, although fewer employ them to predict prognosis 
(46%, 22/48), check for remission (33%, 16/48), or monitor treatment (8%, 4/48) (Figure 2). Length of time on 
treatment is typically used to gauge when to trial patients off treatment (94%, 45/48), although where the young 
person is in relation to important educational milestones, such as examinations, is also frequently considered (79%, 
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38/48). A majority of 81% (39/48) of respondents consider two years as the minimum duration of treatment prior to 
a trial off ATDs, while six respondents reported a year or less and one reported a minimum of five years. 
3.3 Agranulocytosis
All respondents reported that they ‘always’ or ‘usually’ warn their patients about the risk of agranulocytosis before 
starting ATD treatment, with 70% (32/46) reporting they then discuss the risk of agranulocytosis ‘usually’ or ‘at every 
appointment’ during follow up. However, written information about agranulocytosis is ‘rarely’ or ‘never’ provided by 
63% (30/48). When educating patients about how to recognise a possible case of agranulocytosis, the symptoms that 
clinicians mention most frequently to patients are sore throat (98%, 47/48), fever (92%, 44/48) and oral ulcers (44%, 
21/48).
Prior to starting a patient on an ATD, 88% (42/48) measure an FBC. On follow up 28% (13/46) check an FBC every time 
they measure thyroid function and 65% (30/46) ‘on an ad hoc basis’ (Figure 3). Responses to a question seeking the 
definition of agranulocytosis were equally split between correctly identifying this as an absolute neutrophil count 
(ANC) of < 0.5 x109/L (40%, 19/48) and the same proportion defining it as an ANC < 1.0 (40%, 19/48). When asked how 
to manage a low neutrophil count, 35% (17/48) would admit a patient with an ANC < 0.5 x109/L to hospital, whilst 54% 
(26/48) would advise stopping the ATD and rechecking the FBC the next day as an outpatient. The management of a 
low neutrophil count was dependent upon the absolute neutrophil number with 8% (4/48) stopping the ATD at a 
neutrophil count < 2.0 x109/L and 90% (43/48) stopping the ATD at a neutrophil count < 0.5 x109/L (Figure 4).12
Discussion
This is the first nationwide clinician survey studying the current approaches to the management of hyperthyroidism in 
children in the UK. Previous surveys of adult clinicians have shown international variation in the management of 
hyperthyroidism,13,14 but preferences around the use of ATDs in children are unknown.  The response rate of 11% is 
low, but similar to reported rates of less than 20% for online clinician surveys.15 We believe an absolute number of 48 
responses is sufficient to garner insight into current practice in the UK. 
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We identified a preference among clinicians to use the DT approach to ATD administration rather than BR, which is in 
keeping with a 2013 European survey into adult practice.13 Level 1 evidence of superiority of one ATD regimen over 
the other is lacking in paediatric practice. A Cochrane review in 2010, involving primarily adult patients, found relapse 
rates to be similar with both regimens, but a higher rate of side effects when using BR.7 A BR regimen may have the 
advantage of necessitating fewer trips to the outpatients department, but the disadvantage of an extra medication 
burden for the patient,16 and the increased rate of side effects has led the ATA to suggest avoiding this approach. 
Most respondents (85%) use TRAbs to aid diagnosis of Graves’ disease, which have been shown to shorten time to 
diagnosis and reduce management costs.17 TRAbs are also recommended by the ATA and ETA to assist in predicting 
the likelihood of remission and to inform on the decision to wean ATD dose. Adult remission rates of over 80% are 
reported in cohorts with low or undetectable TRAbs compared to 20-30% in cohorts that have persistently elevated 
TRAbs.18,19 Whilst 33% of respondents are monitoring TRAbs for this indication, there is the potential to increase their 
use to improve remission rates in the paediatric cohort. UK clinicians continue patients on ATDs for two years prior to 
a trial off treatment, longer than the 12-18 months suggested in the ATA guidelines, but less than the 3 years suggested 
by the ETA and 5-10 years by the JTA.2-4
Whilst clinicians in this survey report consistently informing patients about the risk of agranulocytosis, the proportion 
who regularly provide written information, as advised in both ATA and ETA guidelines, is low (37%). Although advised, 
neither the ATA nor ETA provide a standardised patient information leaflet. In the UK, the Medicines for Children 
partnership programme have produced a patient information leaflet entitled ‘Carbimazole for hyperthyroidism’.20 This 
is over 1500 words long and, whilst informing patients about the risk of agranulocytosis, does not instruct them beyond 
‘contact your doctor straight away’. The British National Formulary, under ‘important information about Carbimazole’, 
states that CBZ should be stopped pending an FBC should the patient experience symptoms and signs of infection.11 
There is evidence that supplying patient information leaflets about medication increases patient knowledge about side 
effects as well as improving patient satisfaction.21 We postulate that a short, simple patient information leaflet would 
increase the proportion of families and patients receiving and comprehending written information about CBZ. The 
leaflet would aim to increase awareness of agranulocytosis, with specific guidance to stop ATD therapy pending an 
FBC if symptoms of fever, sore throat or oral ulcers occur. These are the most frequent symptoms associated with 
agranulocytosis secondary to ATD use.10
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Agranulocytosis is not the only side effect of CBZ but it is unique in combining frequently experienced and commonly 
innocuous symptoms such as sore throat and fever with a potentially fatal outcome. Pancreatitis has recently been 
highlighted as a recognised side effect,22 alongside the risk of liver dysfunction or vasculitis.2 We believe that these 
conditions have presenting features more likely be recognised as potentially pathological by patients or carers. 
ATA and ETA guidelines recommend a more conservative approach to laboratory proven agranulocytosis than was 
demonstrated by the clinicians responding to our survey. Whilst 90% of respondents would stop the ATD with an ANC 
< 0.5x109/L, only 35% would admit to hospital. It is important to note that rates of death in children with 
agranulocytosis secondary to ATD have been shown to be as high as 4%,23 and thus treatment with intravenous broad-
spectrum antibiotics is recommended.24 However, we are wary of drawing too significant a conclusion from survey 
data into hypothetical patient management decisions, particularly as the option to discuss blood results with an expert 
in the field (i.e. a haematologist) was not available in our multiple choice questions. 
In this survey, 70% of respondents reported they check an FBC with some degree of regularity. Routine monitoring of 
FBC for patients taking ATDs was considered unnecessary by the WHO (World Health Organisation) in 1999 due to the 
often abrupt onset of agranulocytosis.25 This advice is eflected in ETA and ATA guidelines,2,3 although JTA guidelines 
advise undertaking regular monitoring of white cell count during the first 3 months of treatment.4 This timescale is 
consistent with data from UK reports of adverse drug reactions in adults prescribed CBZ showing a median onset of 
agranulocytosis of 31 days (range 14-105)26, although cases have been described that have occurred up to 11 years 
after the start of treatment.27 One potential advantage of checking an FBC at baseline is that it can help to determine 
whether a low white cell count is due to ATD therapy or the disease itself.28
We recognise that our survey has limitations. The response rate was low, although it should be noted that a proportion 
of those receiving the invitation to participate are non-clinicians, some practice mainly or exclusively with patients 
with diabetes and the workload of some endocrinologists is linked to disease areas other than thyroid. Selection bias 
may have influenced the results with those with an interest in thyroid disease being more likely to respond and thus 
disproportionately reporting preferences made by specialists within the field. Recall bias may have influenced such a 
high proportion of respondents (100%) reporting that they always or usually discuss the risk of agranulocytosis with 
patients/carers. A local audit of patient notes in Sheffield revealed only 50% (7/14) of consultations where an ATD was 
initiated included documentation about the risk of agranulocytosis, and no documentation that patients were 
informed to stop the drug should it be suspected.29 Knowledge of adult patients about the risk of agranulocytosis 
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secondary to ATDs has been shown to be poor despite the information being verbally delivered by clinicians,30 
reinforcing the importance of providing this information in the written form.
In conclusion, this survey has shown that choice of ATD and duration of treatment by clinicians in the UK is consistent 
with current international recommendations, although a substantial proportion of children are still managed using a 
BR regimen despite the ATA guideline advising against this practice. The outcome of a UK randomised trial comparing 
biochemical control in young patients managed with either BR and DT is expected imminently and may help to guide 
and refine clinical practice further.31 The measurement of TRAbs to aid diagnosis is a common practice but under-
utilised in relation to detecting likelihood of disease remission and hence the timing of ATD cessation. It appears that 
the majority of clinicians are managing hyperthyroidism without a guideline, perhaps contributing to the variation in 
practice demonstrated, and unable to backup verbal advice about agranulocytosis with written information. Patient 
education is at the heart of patient safety and it seems timely that a national guideline and patient information leaflet 
to support the management of paediatric patients on ATDs is considered.24
Page 10 of 18Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
References
1. Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK 
and Ireland. Clin Endocrinol (Oxf). 2010;72(3):358-363.
2. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and 
Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
3. Kahaly G, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association 
Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal. 2018;7(4):167-186.
4. Minamitani K, Sato H, Ohye H, Harada S, Arisaka O. Guidelines for the treatment of childhood-onset Graves’ 
disease in Japan, 2016. Clin Pediatr Endocrinol. 2017;26(2):29-62.
5. Maia AL, Scheffel RS, Meyer EL, et al. The Brazilian consensus for the diagnosis and treatment of 
hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and 
Metabolism. Arq Bras Endocrinol Metabol. 2013;57(3):205-232.
6. Rivkees SA. 63 Years and 715 Days to the “Boxed Warning”: Unmasking of the Propylthiouracil Problem. Int J 
Pediatr Endocrinol. 2010;2010.
7. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' 
hyperthyroidism. Cochrane Database Syst Rev 2010:CD003420.
8. Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death 
of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol. 2006;154(6):783-786.
9. Benichou C, Solal Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug 
reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr 
Hematol. 1991;33(3):257-262.
10. Sheng WH, Hung CC, Chen YC, et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening 
infections. Qjm. 1999;92(8):455-461.
11. Paediatric Formulary Committee. BNF for Children. Vol 2018-2019: RCPCH Publications Limited; 2018.
12. [dataset] Lawrence N, Cheetham T, Elder C. Paediatric Hyperthyroidism - UK Survey of Clinicians. Figshare. DOI 
https://doi.org/10.6084/m9.figshare.7962839.v1.
13. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the 
management of Graves' disease. Clin Endocrinol (Oxf). 2016;84(1):115-120.
Page 11 of 18 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' 
disease. J Clin Endocrinol Metab. 2012;97(12):4549-4558.
15. Dykema J, Jones NR, Piche T, Stevenson J. Surveying clinicians by web: current issues in design and 
administration. Eval Health Prof. 2013;36(3):352-381.
16. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 
2013;9(12):724-734.
17. McKee A, Peyerl F. TSI Assay Utilization: Impact on Costs of Graves' Hyperthyroidism Diagnosis. American 
Journal of Managed Care. 2012;18(1):E1-E8.
18. Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with 
Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the 
activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. 
Thyroid. 2006;16(3):295-302.
19. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in 
Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized 
study. Eur J Endocrinol. 2008;158(1):69-75.
20. Medicines for Children. Carbimazole for hyperthyroidism. 
https://www.medicinesforchildren.org.uk/carbimazole-hyperthyroidism. Published 2016. Accessed April 2, 
2019.
21. Gibbs S, Waters WE, George CF. Prescription information leaflets: a national survey. J R Soc Med. 
1990;83(5):292-297.
22. Agarwal A. Medicinal products containing carbimazole or thiamazole (synonym: methimazole): (1) 
strengthened advice on contraception and (2) risk of acute pancreatitis [press release]. Direct mailing: 
Amdipharm ltd.2019.
23. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced 
agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98(12):4776-4783.
24. Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on 
Diagnosis and Management. In: Drugs R D. Vol 17.2017:91-96.
Page 12 of 18Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
25. The Committee on Safety of Medicines [World Health Organisation]. WHO Pharmaceuticals Newsletter 1999, 
No. 03&04: Drug surveillance: Anti-thyroid drugs: agranulocytosis: UK. 
http://apps.who.int/medicinedocs/en/d/Js2271e/2.3.html. Published 1999. Accessed April 2, 2019.
26. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin 
Endocrinol (Oxf). 2004;61(5):589-594.
27. Mutharasan P, Oatis W, Kwaan H, Molitch M. Delayed anithyroid drug-induced agranulocytosis. Endocr Pract. 
2012;18(4):e69-72.
28. Aggarwal N, Tee SA, Saqib W, Fretwell T, Summerfield GP, Razvi S. Treatment of hyperthyroidism with 
antithyroid drugs corrects mild neutropenia in Graves' disease. Clin Endocrinol (Oxf). 2016;85(6):949-953.
29. [dataset] Lawrence N, Elder C. Local Use of Anti-Thyroid Drugs in Sheffield. Figshare. 
https://doi.org/10.6084/m9.figshare.7962860.v1.
30. Robinson J, Richardson M, Hickey J, et al. Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis. Eur 
Thyroid J. 2014;3(4):245-251.
31. Cheetham T. Study of two anti-thyroid drug treatment regimens in young people with thyrotoxicosis. Springer 
Nature. ISRTCN Registry Web site. http://www.isrctn.com/ISRCTN82088322. Published 2011. Updated 
23/01/2018. Accessed April 2, 2019.
Page 13 of 18 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 14 of 18Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 1: Preference for Anti-Thyroid Drug Treatment Regimen 
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Figure 2: The Measurement of TRAbs in relation to ATD treatment
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Figure 3: The measurement of FBC in relation to ATD treatment
Every time 
they have 
their TFTs 
checked
On an ad hoc 
basis
Periodically, 
but not every 
time they 
have their 
TFTs checked
Within 2 
weeks of 
starting the 
ATD
Within 6 
weeks of 
starting the 
ATD
Within 12 
weeks of 
starting the 
ATD
0
5
10
15
20
25
30
Generally, when reviewing a child who is already taking an ATD, how 
often do you measure their full blood count?
N
um
be
r o
f r
es
po
nd
en
ts
FBC = Full Blood Count. ATD = Anti-Thyroid Drug. TFT = Thyroid Function Test
Page 17 of 18 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 4: Actions clinicians recommend after a low ANC
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